Hepatic and pancreatic damage produced by cytotoxic drugs.
D000609:Aminoacridines / Q000009:adverse effects; D000677:Amsacrine; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001215:Asparaginase / Q000009:adverse effects; D001379:Azathioprine / Q000009:adverse effects; D002699:Chlorambucil / Q000009:adverse effects; D003606:Dacarbazine / Q000009:adverse effects; D004359:Drug Therapy, Combination; D006801:Humans; D007364:Intercalating Agents / Q000009:adverse effects; D008099:Liver / Q000187:drug effects*; D015122:Mercaptopurine / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects; D009607:Nitrosourea Compounds / Q000009:adverse effects; D010179:Pancreas / Q000187:drug effects*; D008926:Plicamycin / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D011763:Pyrrolizidine Alkaloids / Q000009:adverse effects; D013311:Streptozocin / Q000009:adverse effects
D000609:Aminoacridines; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D007364:Intercalating Agents; D009607:Nitrosourea Compounds; D011763:Pyrrolizidine Alkaloids; D000677:Amsacrine; D002699:Chlorambucil; D011344:Procarbazine; C013095:indicine-N-oxide; D013311:Streptozocin; D003606:Dacarbazine; D015122:Mercaptopurine; D001215:Asparaginase; D001379:Azathioprine; D008926:Plicamycin; D008727:Methotrexate